---
title: "Virax Biolabs signs Fosun Diagnostics supply deal for ImmuneSelect in six Southeast Asian markets"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292898428.md"
description: "Virax Biolabs signed a commercial supply agreement with Fosun Diagnostics for its ImmuneSelect product across six Southeast Asian markets. The deal focuses on near-term supply and evaluation, initially targeting tuberculosis research in Thailand. Virax aims to leverage Fosun's network for potential regional expansion to convert demand into revenue."
datetime: "2026-07-16T11:33:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292898428.md)
  - [en](https://longbridge.com/en/news/292898428.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292898428.md)
generator: "portal-rs"
---

# Virax Biolabs signs Fosun Diagnostics supply deal for ImmuneSelect in six Southeast Asian markets

-   Virax Biolabs entered a commercial supply agreement with Fosun Diagnostics for ImmuneSelect across six Southeast Asian markets. \* Deal targets near-term commercial supply and evaluation activity, with initial focus on tuberculosis-related research applications in Thailand. \* Management flagged potential regional expansion through Fosun’s network as it seeks to translate ImmuneSelect demand into revenue. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [VRAX.US](https://longbridge.com/en/quote/VRAX.US.md)
- [02196.HK](https://longbridge.com/en/quote/02196.HK.md)
- [600196.CN](https://longbridge.com/en/quote/600196.CN.md)

## Related News & Research

- [FOSUN PHARMA  Opens 2.78% Higher After Proposing Up to HKD1B H Share Buyback](https://longbridge.com/en/news/298152618.md)
- [Fosun Pharma Industrial wins China approval for FXS5626 vitiligo Phase II/III trial](https://longbridge.com/en/news/298295063.md)
- [Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors](https://longbridge.com/en/news/297890174.md)
- [Dexxos Participações buyback adds 85,900 common shares, spending R$ 608,425](https://longbridge.com/en/news/298315564.md)
- [Valid Soluções buys back 50,000 common shares for R$ 886,585](https://longbridge.com/en/news/298361998.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**